• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
GSK-461364

GSK-461364

Product ID G7241
Cas No. 929095-18-1
Purity ≥99%
Product Unit SizeCostQuantityStock
1 mg $127.90 In stock
5 mg $216.20 In stock
10 mg $337.60 In stock
25 mg $601.00 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

GSK-461364 is an inhibitor of polo-like kinase 1 (PLK1) that is currently in clinical trials as a potential treatment for solid tumor cancers. GSK-461364 displays anticancer chemotherapeutic activity as well as anticoagulant activity. This compound inhibits glioblastoma cell proliferation, invasion, and colony formation and induces apoptosis and G2 phase cell cycle arrest.

Product Info

Cas No.

929095-18-1

Purity

≥99%

Formula

C27H28F3N5O2S

Formula Wt.

543.60

IUPAC Name

5-{6-[(4-Methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl}-3-{(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy}-2-thiophenecarboxamide

Solubility

Ethanol 30 mg/mL (55.18 mM) DMSO 10 mg/mL (18.39 mM) Water Insoluble

Appearance

White to off white powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

G7241 MSDS PDF

Info Sheet

G7241 Info Sheet PDF

References

Yim H. Current clinical trials with polo-like kinase 1 inhibitors in solid tumors. Anticancer Drugs. 2013 Nov;24(10):999-1006. PMID: 23949254.

Pezuk JA, Brassesco MS, Morales AG, et al. Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma. Cancer Gene Ther. 2013 Sep;20(9):499-506. PMID: 23887645.

Olmos D, Barker D, Sharma R, et al. Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res. 2011 May 15;17(10):3420-30. PMID: 21459796.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • T1002

    2-Debenzoyl Paclitaxel-2-(2-Methyl-2-Butenoate)

    Synthesis intermediate

    ≥95%
  • B807214

    Buflomedil Hydrochloride

    Alpha blocker and vasoactive agent.

    ≥99%
  • E537333

    Enniatin A1

    Mycotoxin contaminant found in cereal grains.

    ≥98%
  • T7132

    Triacetyl Resveratrol

    Resveratrol prodrug; potential SIRT1 activator....

    ≥99%
  • I0902

    Icaritin

    Flavonoid found in Epimedium.

    ≥98%
  • T2800

    Thalidomide

    Immunomodulator; teratogen.

    ≥98%
  • R2711

    Recombinant HCV-Core Antigens

    Recombinant HIV core protein antigen fragment.<...

    ≥95%
  • C5970

    Corydaline

    Alkaloid compound found in Corydalis.

    ≥94%
  • D1859

    2-Deoxy-D-glucose

    Glucose metabolism inhibitor, N-linked glycosyl...

    ≥99%
  • E5217

    β-Endorphin, human

    Endogenous opioid peptide; μOR agonist.

    ≥95%
  • V3345

    Vildagliptin

    DPP4 inhibitor.

    ≥98%
  • C0824

    CCG1423

    Serum response factor inhibitor and MRTF-A bind...

    ≥98%
  • T3099

    Thymus Factor

    Endogenous peptide, involved in immune signalin...

    ≥95%
  • P3348

    Pimecrolimus

    Calcineurin inhibitor, potential TRPV1 agonist....

    ≥99%
  • F4480

    5-Fluorouracil

    Pyrimidine analog; inhibits thymidylate synthas...

    ≥98%
  • M0262

    Maprotiline Hydrochloride

    Tetracycline; FIASMA, histamine H1, 5-HT2, mACh...

    ≥98%
  • N3210

    Nicergoline

    Ergot derivative found in Claviceps; α1-adrene...

    ≥98%
  • T0153

    Tanshinone I

    Diterpene found in Salvia.

    ≥95%
  • C104762

    CCT-245737

    CHK1 inhibitor.

    ≥98%
  • P200002

    PF-07321332

    Inhibitor of coronaviruses

    ≥99%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only